Compared to cells with re-expression of vector or non-glycosylated B7H3, cells with re-expression of glycosylated B7H3 were more resistant to killing by CD3/CD28-activated human T cells, as confirmed by the decreased percentage of lysed (cleaved caspase-3+ and LDH+) tumor cells (Fig. 4c, d, Supplementary Fig. 3a). This evidence concerns the gene CD28 and neoplasm.